e-Drug3D

2148

VANZACAFTOR

INN
VANZACAFTOR

cas 2374124-49-7

CLASS

RESPIRATORY
TREATMENT OF CYSTIC FIBROSIS (CF)

ROUTE (list)

ORAL

ATC code

R07AX33

PK parameters

Tmax 7.8 HOUR
VD 121 LITER
Cl 1.34 LITER / HOUR
PPB 99 PERCENT
t1/2 92.8 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET CFTR

DrugCentral

Download SDF file

13H-17,20-Methano-8,12-nitrilo-12H-pyrido[3,2-d][1,2,6,13]thiatriazacyclooctadecin-5(6H)-one, 2-[3-(2-dispiro[2.0.2.1]hept-7-ylethoxy)-1H-pyrazol-1-yl]-14,15,16,17,18,19-hexahydro-19,19-dimethyl-, 7,7-dioxide, (17S)- (ACI)

Formula:
C32H39N7O4S

Calculated chemical properties:

MW 617.77
NB_atoms 44
XLogP 4.08
PSA 116.526
NB_HD 2
NB_HA 11
fsp3 0.56
Lipinski(0=no;1=yes) 0

FDA
NDA 218730 (label) INN (IVACAFTOR ; TEZACAFTOR ; VANZACAFTOR CALCIUM) ALYFTREK (VERTEX PHARMS INC) APPROVAL= AP YEAR= 2024 NEWMOLECULARENTITY